The Clinical Utility of salivary oxytocin as a putatively surrogate early Risk Identification biomarker of nascent Metabolic Syndrome with and without prediabetes

09.May.2023

​

​Bulatova, N. R., Kasabri, V. N., Albsoul, A. M., Halaseh, L., & Suyagh, M. (2023). The Clinical Utility of salivary oxytocin as a putatively surrogate early Risk Identification biomarker of nascent Metabolic Syndrome with and without prediabetes. https://doi.org/10.21203/rs.3.rs-2587738/v1 ​